Chinese General Practice ›› 2022, Vol. 25 ›› Issue (08): 937-944.DOI: 10.12114/j.issn.1007-9572.2022.02.010
Special Issue: 肿瘤最新文章合集
• Original Research • Previous Articles Next Articles
Bioinformatic Analysis of Potential Key Genes in Castration-resistant Prostate Cancer Development
1.Department of Urology,North China University of Science and Technology Affiliated Hospital,Tangshan 063000,China
2.School of Public Health,North China University of Science and Technology,Tangshan 063210,China
3.Modern Education Technology Center,North China University of Science and Technology,Tangshan 063000,China
*Corresponding authors:SHEN Hong,Engineer;E-mail:shenhong@ncst.edu.cn
CAO Fenghong,Chief physician,Master supervisor;E-mail:caofenghong@163.com
Received:
2021-10-11
Revised:
2021-12-20
Published:
2022-03-15
Online:
2022-03-02
通讯作者:
沈宏,曹凤宏
基金资助:
CLC Number:
DONG Jingting, HENG Li, KANG Shaosan, LIU Jian, TIAN Zhichong, ZHANG Liguo, ZHANG Jincun, LI Zhiguo, SHEN Hong, CAO Fenghong.
Bioinformatic Analysis of Potential Key Genes in Castration-resistant Prostate Cancer Development [J]. Chinese General Practice, 2022, 25(08): 937-944.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.02.010
ID | 描述 |
---|---|
GO:0030198 | 细胞外基质组织 |
GO:0007155 | 细胞黏附 |
GO:0051301 | 细胞分裂 |
GO:0030199 | 胶原纤维组织 |
GO:0030574 | 胶原蛋白分解代谢过程 |
GO:0000070 | 有丝分裂姐妹染色单体分离 |
GO:0006909 | 吞噬作用 |
GO:0007067 | 有丝分裂核分裂 |
GO:0051988 | 调节纺锤体微管与着丝点附着 |
GO:0000281 | 有丝分裂胞质分裂 |
Table 1 Major biological processes in which differentially expressed genes in castration-resistant prostate cancer being involved
ID | 描述 |
---|---|
GO:0030198 | 细胞外基质组织 |
GO:0007155 | 细胞黏附 |
GO:0051301 | 细胞分裂 |
GO:0030199 | 胶原纤维组织 |
GO:0030574 | 胶原蛋白分解代谢过程 |
GO:0000070 | 有丝分裂姐妹染色单体分离 |
GO:0006909 | 吞噬作用 |
GO:0007067 | 有丝分裂核分裂 |
GO:0051988 | 调节纺锤体微管与着丝点附着 |
GO:0000281 | 有丝分裂胞质分裂 |
ID | 描述 |
---|---|
GO:0070062 | 细胞外外泌体 |
GO:0031012 | 细胞外基质 |
GO:0005578 | 蛋白质细胞外基质 |
GO:0005615 | 细胞外空隙 |
GO:0030496 | 中间体 |
GO:0005788 | 内质网腔 |
GO:0005581 | 胶原蛋白三聚物 |
GO:0005737 | 细胞质 |
GO:0051233 | 中央区 |
GO:0005604 | 基底膜 |
Table 2 Major cellular components of differentially expressed genes involved in castration-resistant prostate cancer development
ID | 描述 |
---|---|
GO:0070062 | 细胞外外泌体 |
GO:0031012 | 细胞外基质 |
GO:0005578 | 蛋白质细胞外基质 |
GO:0005615 | 细胞外空隙 |
GO:0030496 | 中间体 |
GO:0005788 | 内质网腔 |
GO:0005581 | 胶原蛋白三聚物 |
GO:0005737 | 细胞质 |
GO:0051233 | 中央区 |
GO:0005604 | 基底膜 |
ID | 描述 |
---|---|
GO:0005201 | 细胞外基质结构成分 |
GO:0005515 | 蛋白质结合 |
GO:0005518 | 胶原蛋白质结合 |
GO:0050840 | 细胞外基质结合 |
GO:0005178 | 整合素结合 |
GO:0008307 | 肌肉结构成分 |
GO:0048407 | 血小板衍生生长因子结合 |
GO:0019901 | 蛋白激酶结合 |
GO:0008201 | 肝素结合 |
GO:0051015 | 肌动蛋白丝结合 |
Table 3 Major molecular functions of differentially expressed genes involved in castration-resistant prostate cancer development
ID | 描述 |
---|---|
GO:0005201 | 细胞外基质结构成分 |
GO:0005515 | 蛋白质结合 |
GO:0005518 | 胶原蛋白质结合 |
GO:0050840 | 细胞外基质结合 |
GO:0005178 | 整合素结合 |
GO:0008307 | 肌肉结构成分 |
GO:0048407 | 血小板衍生生长因子结合 |
GO:0019901 | 蛋白激酶结合 |
GO:0008201 | 肝素结合 |
GO:0051015 | 肌动蛋白丝结合 |
关键基因 | logFC | P值 | MCC | DMNC | MNC |
---|---|---|---|---|---|
CDC20 | 1.406 196 669 | 3.45E-07 | 9.22E+13 | 1.387 59 | 46 |
CCNB2 | 1.211 615 251 | 6.41E-05 | 9.22E+13 | 1.372 69 | 46 |
PRC1 | 1.379 662 195 | 2.93E-06 | 9.22E+13 | 1.366 72 | 46 |
MAD2L1 | 1.344 235 673 | 0.000 588 11 | 9.22E+13 | 1.366 72 | 46 |
PBK | 2.292 914 566 | 3.17E-05 | 9.22E+13 | 1.406 38 | 45 |
NUSAP1 | 1.570 694 653 | 2.92E-07 | 9.22E+13 | 1.394 00 | 45 |
RRM2 | 1.412 761 198 | 3.44E-07 | 9.22E+13 | 1.381 63 | 45 |
SMC2 | 1.412 009 936 | 1.67E-07 | 9.22E+13 | 1.358 42 | 45 |
MELK | 2.012 790 040 | 6.81E-09 | 9.22E+13 | 1.432 21 | 44 |
KIF4A | 2.302 338 169 | 3.25E-09 | 9.22E+13 | 1.420 96 | 44 |
DTL | 1.385 254 880 | 1.29E-05 | 9.22E+13 | 1.408 10 | 44 |
ZWINT | 1.591 711 536 | 0.000 340 659 | 9.22E+13 | 1.372 74 | 44 |
CEP55 | 1.779 583 266 | 1.70E-05 | 9.22E+13 | 1.440 82 | 43 |
RACGAP1 | 1.577 983 649 | 5.87E-08 | 9.22E+13 | 1.440 82 | 43 |
CDKN3 | 2.135 599 175 | 0.000 218 876 | 9.22E+13 | 1.360 59 | 43 |
Table 4 Details of key genes of differentially expressed genes involved in castration-resistant prostate cancer development
关键基因 | logFC | P值 | MCC | DMNC | MNC |
---|---|---|---|---|---|
CDC20 | 1.406 196 669 | 3.45E-07 | 9.22E+13 | 1.387 59 | 46 |
CCNB2 | 1.211 615 251 | 6.41E-05 | 9.22E+13 | 1.372 69 | 46 |
PRC1 | 1.379 662 195 | 2.93E-06 | 9.22E+13 | 1.366 72 | 46 |
MAD2L1 | 1.344 235 673 | 0.000 588 11 | 9.22E+13 | 1.366 72 | 46 |
PBK | 2.292 914 566 | 3.17E-05 | 9.22E+13 | 1.406 38 | 45 |
NUSAP1 | 1.570 694 653 | 2.92E-07 | 9.22E+13 | 1.394 00 | 45 |
RRM2 | 1.412 761 198 | 3.44E-07 | 9.22E+13 | 1.381 63 | 45 |
SMC2 | 1.412 009 936 | 1.67E-07 | 9.22E+13 | 1.358 42 | 45 |
MELK | 2.012 790 040 | 6.81E-09 | 9.22E+13 | 1.432 21 | 44 |
KIF4A | 2.302 338 169 | 3.25E-09 | 9.22E+13 | 1.420 96 | 44 |
DTL | 1.385 254 880 | 1.29E-05 | 9.22E+13 | 1.408 10 | 44 |
ZWINT | 1.591 711 536 | 0.000 340 659 | 9.22E+13 | 1.372 74 | 44 |
CEP55 | 1.779 583 266 | 1.70E-05 | 9.22E+13 | 1.440 82 | 43 |
RACGAP1 | 1.577 983 649 | 5.87E-08 | 9.22E+13 | 1.440 82 | 43 |
CDKN3 | 2.135 599 175 | 0.000 218 876 | 9.22E+13 | 1.360 59 | 43 |
[1] | CHUNG B H, HORIE S, CHIONG E. Clinical studies investigating the use of leuprorelin for prostate cancer in Asia[J]. Prostate Int,2020,8(1):1-9. DOI:10.1016/j.prnil.2019.06.001. |
[2] | SANTER F R, ERB H H H, MCNEILL R V. Therapy escape mechanisms in the malignant prostate[J]. Semin Cancer Biol,2015,35:133-144. DOI:10.1016/j.semcancer.2015.08.005. |
[3] | KIRBY M, HIRST C, CRAWFORD E D. Characterising the castration-resistant prostate cancer population:a systematic review[J]. Int J Clin Pract,2011,65(11):1180-1192. DOI:10.1111/j.1742-1241.2011.02799.x. |
[4] | HARRIS W P, MOSTAGHEL E A, NELSON P S,et al. Androgen deprivation therapy:progress in understanding mechanisms of resistance and optimizing androgen depletion[J]. Nat Clin Pract Urol,2009,6(2):76-85. DOI:10.1038/ncpuro1296. |
[5] | PUNIT S, DRABOVICH A P, JARVI K A,et al. Mechanisms of androgen-independent prostate cancer[J]. EJIFCC,2014,25(1):42-54. |
[6] | GUO J S, GU Y Z, MA X Y,et al. Identification of hub genes and pathways in adrenocortical carcinoma by integrated bioinformatic analysis[J]. J Cell Mol Med,2020,24(8):4428-4438. DOI:10.1111/jcmm.15102. |
[7] | SUN Z L, MAO Y H, ZHANG X,et al. Identification of ARHGEF38,NETO2,GOLM1,and SAPCD2 associated with prostate cancer progression by bioinformatic analysis and experimental validation[J]. Front Cell Dev Biol,2021,9:718638. DOI:10.3389/fcell.2021.718638. |
[8] | SHEN H, GUO Y L, LI G H,et al. Gene expression analysis reveals key genes and signalings associated with the prognosis of prostate cancer[J]. Comput Math Methods Med,2021,2021:9946015. DOI:10.1155/2021/9946015. |
[9] | GU P, YANG D R, ZHU J,et al. Bioinformatics analysis identified hub genes in prostate cancer tumorigenesis and metastasis[J]. Math Biosci Eng,2021,18(4):3180-3196. DOI:10.3934/mbe.2021158. |
[10] | PARRISH R S, SPENCER H J 3rd. Effect of normalization on significance testing for oligonucleotide microarrays[J]. J Biopharm Stat,2004,14(3):575-589. DOI:10.1081/BIP-200025650. |
[11] | FERREIRA J A. The Benjamini-Hochberg method in the case of discrete test statistics[J]. Int J Biostat,2007,3(1):Article11. DOI:10.2202/1557-4679.1065. |
[12] | HUANG D W, SHERMAN B T, LEMPICKI R A. Bioinformatics enrichment tools:paths toward the comprehensive functional analysis of large gene lists[J]. Nucleic Acids Res,2009,37(1):1-13. DOI:10.1093/nar/gkn923. |
[13] | ASHBURNER M, BALL C A, BLAKE J A,et al. Gene ontology:tool for the unification of biology. The Gene Ontology Consortium[J]. Nat Genet,2000,25(1):25-29. DOI:10.1038/75556. |
[14] | OGATA H, GOTO S, SATO K,et al. KEGG:Kyoto encyclopedia of genes and genomes[J]. Nucleic Acids Res,1999,27(1):29-34. DOI:10.1093/nar/27.1.29. |
[15] | WALTER W, SÁNCHEZ-CABO F, RICOTE M. GOplot:an R package for visually combining expression data with functional analysis[J]. Bioinformatics,2015,31(17):2912-2914. DOI:10.1093/bioinformatics/btv300. |
[16] | SNEL B, LEHMANN G, BORK P,et al. STRING:a web-server to retrieve and display the repeatedly occurring neighbourhood of a gene[J]. Nucleic Acids Res,2000,28(18):3442-3444. DOI:10.1093/nar/28.18.3442. |
[17] | SAITO R, SMOOT M E, ONO K,et al. A travel guide to Cytoscape plugins[J]. Nat Methods,2012,9(11):1069-1076. DOI:10.1038/nmeth.2212. |
[18] | BADER G D, HOGUE C W V. An automated method for finding molecular complexes in large protein interaction networks[J]. BMC Bioinformatics,2003,4:2. DOI:10.1186/1471-2105-4-2. |
[19] | GUO Y Z, SUN H H, WANG X T,et al. Transcriptomic analysis reveals key lncRNAs associated with ribosomal biogenesis and epidermis differentiation in head and neck squamous cell carcinoma[J]. J Zhejiang Univ Sci B,2018,19(9):674-688. DOI:10.1631/jzus.B1700319. |
[20] | TANG Z F, LI C W, KANG B X,et al. GEPIA:a web server for cancer and normal gene expression profiling and interactive analyses[J]. Nucleic Acids Res,2017,45(W1):W98-102. DOI:10.1093/nar/gkx247. |
[21] | ROBIN X, TURCK N, HAINARD A,et al. pROC:an open-source package for R and S+ to analyze and compare ROC curves[J]. BMC Bioinformatics,2011,12:77. DOI:10.1186/1471-2105-12-77. |
[22] | YAO F, ZHU Z F, WEN J,et al. PODN is a prognostic biomarker and correlated with immune infiltrates in osteosarcoma[J]. Cancer Cell Int,2021,21(1):381. DOI:10.1186/s12935-021-02086-5. |
[23] | CHANDRASEKAR T, YANG J C, GAO A C,et al. Mechanisms of resistance in castration-resistant prostate cancer (CRPC)[J]. Transl Androl Urol,2015,4(3):365-380. DOI:10.3978/j.issn.2223-4683.2015.05.02. |
[24] | MARCUS A I, PETERS U, THOMAS S L,et al. Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and-sensitive cancer cells[J]. J Biol Chem,2005,280(12):11569-11577. DOI:10.1074/jbc.M413471200. |
[25] | HE H Q, HAO J, DONG X,et al. ZRSR2 overexpression is a frequent and early event in castration-resistant prostate cancer development[J]. Prostate Cancer Prostatic Dis,2021,24(3):775-785. DOI:10.1038/s41391-021-00322-7. |
[26] | WANG Q, LI Z A, YANG J,et al. Loss of NEIL3 activates radiotherapy resistance in the progression of prostate cancer[J]. Cancer Biol Med,2021. DOI:10.20892/j.issn.2095-3941.2020.0550. |
[27] | KIM M Y, JUNG A R, SHIN D,et al. Niclosamide exerts anticancer effects through inhibition of the FOXM1-mediated DNA damage response in prostate cancer[J]. Am J Cancer Res,2021,11(6):2944-2959. |
[28] | YU H T. Cdc20:a WD40 activator for a cell cycle degradation machine[J]. Mol Cell,2007,27(1):3-16. DOI:10.1016/j.molcel.2007.06.009. |
[29] | GAYYED M F, EL-MAQSOUD N M, TAWFIEK E R,et al. A comprehensive analysis of CDC20 overexpression in common malignant tumors from multiple organs:its correlation with tumor grade and stage[J]. Tumour Biol,2016,37(1):749-762. DOI:10.1007/s13277-015-3808-1. |
[30] | WANG L X, YANG C L, CHU M,et al. Cdc20 induces the radioresistance of bladder cancer cells by targeting FoxO1 degradation[J]. Cancer Lett,2021,500:172-181. DOI:10.1016/j.canlet.2020.11.052. |
[31] | YANG G, WANG G, XIONG Y F,et al. CDC20 promotes the progression of hepatocellular carcinoma by regulating epithelial-mesenchymal transition[J]. Mol Med Rep,2021,24(1):483. DOI:10.3892/mmr.2021.12122. |
[32] | DAI L, SONG Z X, WEI D P,et al. CDC20 and PTTG1 are important biomarkers and potential therapeutic targets for metastatic prostate cancer[J]. Adv Ther,2021,38(6):2973-2989. DOI:10.1007/s12325-021-01729-3. |
[33] | ZHANG Q, HUANG H, LIU A,et al. Cell division cycle 20 (CDC20) drives prostate cancer progression via stabilization of β-catenin in cancer stem-like cells[J]. EBioMedicine,2019,42:397-407. DOI:10.1016/j.ebiom.2019.03.032. |
[34] | LI K, MAO Y H, LU L,et al. Silencing of CDC20 suppresses metastatic castration-resistant prostate cancer growth and enhances chemosensitivity to docetaxel[J]. Int J Oncol,2016,49(4):1679-1685. DOI:10.3892/ijo.2016.3671. |
[35] | TO-HO K W, CHEUNG H W, LING M T,et al. MAD2DeltaC induces aneuploidy and promotes anchorage-independent growth in human prostate epithelial cells[J]. Oncogene,2008,27(3):347-357. DOI:10.1038/sj.onc.1210633. |
[36] | WU Y, TAN L M, CHEN J J,et al. MAD2 combined with mitotic spindle apparatus (MSA) and anticentromere antibody (ACA) for diagnosis of small cell lung cancer (SCLC)[J]. Med Sci Monit,2018,24:7541-7547. DOI:10.12659/MSM.909772. |
[37] | LI Y H, BAI W J, ZHANG J J. miR-200c-5p suppresses proliferation and metastasis of human hepatocellular carcinoma (HCC) via suppressing MAD2L1[J]. Biomed Pharmacother,2017,92:1038-1044. DOI:10.1016/j.biopha.2017.05.092. |
[38] | CHOI J W, KIM Y, LEE J H,et al. High expression of spindle assembly checkpoint proteins CDC20 and MAD2 is associated with poor prognosis in urothelial bladder cancer[J]. Virchows Arch,2013,463(5):681-687. DOI:10.1007/s00428-013-1473-6. |
[39] | RAEMAEKERS T, RIBBECK K, BEAUDOUIN J,et al. NuSAP,a novel microtubule-associated protein involved in mitotic spindle organization[J]. J Cell Biol,2003,162(6):1017-1029. DOI:10.1083/jcb.200302129. |
[40] | GORDON C A, GONG X, GANESH D,et al. NUSAP1 promotes invasion and metastasis of prostate cancer[J]. Oncotarget,2017,8(18):29935-29950. DOI:10.18632/oncotarget.15604. |
[41] | GULZAR Z G, MCKENNEY J K, BROOKS J D. Increased expression of NuSAP in recurrent prostate cancer is mediated by E2F1[J]. Oncogene,2013,32(1):70-77. DOI:10.1038/onc.2012.27. |
[42] | GORDON C A, GULZAR Z G, BROOKS J D. NUSAP1 expression is upregulated by loss of RB1 in prostate cancer cells[J]. Prostate,2015,75(5):517-526. DOI:10.1002/pros.22938. |
[43] | WU Y G, LIU H X, GONG Y F,et al. ANKRD22 enhances breast cancer cell malignancy by activating the Wnt/β-catenin pathway via modulating NuSAP1 expression[J]. Bosn J Basic Med Sci,2021,21(3):294-304. DOI:10.17305/bjbms.2020.4701. |
[44] | GUO H, ZOU J P, ZHOU L,et al. NUSAP1 promotes gastric cancer tumorigenesis and progression by stabilizing the YAP1 protein[J]. Front Oncol,2020,10:591698. DOI:10.3389/fonc.2020.591698. |
[45] | ZHANG Y Y, HUANG K T, CAI H H,et al. The role of nucleolar spindle-associated protein 1 in human ovarian cancer[J]. J Cell Biochem,2020,121(11):4397-4405. DOI:10.1002/jcb.29661. |
[46] | XU Z Y, WANG Y, XIONG J,et al. NUSAP1 knockdown inhibits cell growth and metastasis of non-small-cell lung cancer through regulating BTG2/PI3K/Akt signaling[J]. J Cell Physiol,2020,235(4):3886-3893. DOI:10.1002/jcp.29282. |
[47] | GAO S, YIN H B, TONG H,et al. Nucleolar and spindle associated protein 1 (NUSAP1) promotes bladder cancer progression through the TGF-β signaling pathway[J]. Onco Targets Ther,2020,13:813-825. DOI:10.2147/OTT.S237127. |
[48] | LI H, ZHANG W J, YAN M,et al. Nucleolar and spindle associated protein 1 promotes metastasis of cervical carcinoma cells by activating Wnt/β-catenin signaling[J]. J Exp Clin Cancer Res,2019,38(1):33. DOI:10.1186/s13046-019-1037-y. |
[49] | LIU Z X, GUAN C Q, LU C H,et al. High NUSAP1 expression predicts poor prognosis in colon cancer[J]. Pathol Res Pract,2018,214(7):968-973. DOI:10.1016/j.prp.2018.05.017. |
[1] | JIN Tongtong, WU Wangjian, FU Hao, HE Wanbin, ZHOU Fenghai. Risk Factors for Positive Surgical Margins after Radical Prostatectomy in Chinese Men: a Meta-analysis [J]. Chinese General Practice, 2023, 26(17): 2147-2154. |
[2] | CHAI Yan, ZHAO Yuqing, GUO Xunan, WANG Dongying, BIAN Yunfei. Bioinformatics Analysis of the Role of Epicardial Adipose Tissue in Coronary Artery Disease [J]. Chinese General Practice, 2023, 26(08): 939-950. |
[3] |
HENG Li, ZHANG Liguo, DONG Jingting, LI Zhiguo, CAO Fenghong.
Molecular Mechanism of Oxidative Stress Mediated Androgen Receptor Signal Reactivation in Prostatic Cancer Progression [J]. Chinese General Practice, 2022, 25(05): 636-642. |
[4] | DAN Lijuan,CHAI Shaozhu,LI Guiyu,SU Yue,ZOU Jiaxi,WEN Li. Differentially Expressed Proteins and Their Regulation between Liver-gallbladder Damp-heat Syndrome and Spleen-stomach Damp-heat Syndrome in Chronic Hepatitis B [J]. Chinese General Practice, 2021, 24(3): 348-354. |
[5] | WANG Hui,ZHAO Shankun,LIU Shixiong,LI Xin. The Treatment Value of Taking Twice Abiraterone Acetate for the Metastatic Prostate Cancer [J]. Chinese General Practice, 2021, 24(26): 3387-3391. |
[6] | LI Fan,XU Bin,XIANG Hui,CHEN Zejia,PANG Zisen,ZHANG Tianyu. Diagnostic Value of Circulating Cell-free DNA to Prostate Cancer:a Meta-analysis [J]. Chinese General Practice, 2021, 24(20): 2580-2588. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||